0001193125-26-216746.txt : 20260511 0001193125-26-216746.hdr.sgml : 20260511 20260511160509 ACCESSION NUMBER: 0001193125-26-216746 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20260511 DATE AS OF CHANGE: 20260511 EFFECTIVENESS DATE: 20260511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PureTech Health plc CENTRAL INDEX KEY: 0001782999 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39670 FILM NUMBER: 26963108 BUSINESS ADDRESS: STREET 1: 6 TIDE STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 6 TIDE STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 25 1 d54446d25.htm 25 25
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM 25

 

 

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-39670

 

 

PURETECH HEALTH PLC

THE NASDAQ GLOBAL MARKET

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

 

 

6 Tide Street, Suite 400

Boston, Massachusetts 02210 (617) 482-2333

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

American Depositary Shares, each representing 10 ordinary shares, par value £0.01 per share

(Description of class of securities)

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

☐

17 CFR 240.12d2-2(a)(1)

☐

17 CFR 240.12d2-2(a)(2)

☐

17 CFR 240.12d2-2(a)(3)

☐

17 CFR 240.12d2-2(a)(4)

☐

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

☒

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, PureTech Health plc certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

Date: May 11, 2026     By:  

/s/ Robert Lyne

    Name:   Robert Lyne
    Title:   Chief Executive Officer